SHIELDS: Safety and Performance of a Synthetic Tissue Sealant in Reducing Fluid Leakage in Hepatobiliary and Pancreatic Surgery

• Sponsor: Polyganics BV (Industry)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT04024956
• Collaborator: Genae (Industry)
• Enrollment: 80
• Locations: 2
• Arm: 1
• Anticipated Duration (Months): 19.2
• Patients Per Site: 40
• Patients Per Site Per Month: 2.1

Study Details

Study Description

Brief Summary

Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans.

This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas.

The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy.

The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.

Condition or Disease	Intervention/Treatment	Phase
Pancreatectomy; Hepatic Resection	Device: Sealing Device	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 80 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Open-label, single-arm, multicenter studyOpen-label, single-arm, multicenter study
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Prospective, Multicenter Study to Evaluate the Safety and Performance of a syntHetic Tissue Sealant in Reducing fluId lEakage Following Elective hepatobiLiary anD Pancreatic Surgery
• Actual Study Start Date: Aug 25, 2020
• Actual Primary Completion Date: Nov 19, 2021
• Anticipated Study Completion Date: Apr 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sealing Device Sealing Device applied in hepatic resection or distal pancreatectomy	Device: Sealing Device; The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.

Outcome Measures

Primary Outcome Measures

1. Bile leakage [30 days]

   Incidence of post-operative bile leakage (International Study Group of Liver Surgery Bile leakage Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C

2. Pancreatic leakage [30 days]

   Incidence of post-operative pancreatic juice leakage (International Study Group of Pancreas Surgery Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C

Secondary Outcome Measures

1. Bleeding [Day 1]

   Intra-operative control bleeding

2. Leak-associated comorbidities [16 months]

   Incidence of leak-associated comorbidities

3. re-intervention [16 months]

   Incidence of re-intervention

4. Ease of Use [Day 1]

   Ease of Use of the device as measured by questionnaire

5. Post-operative bile leakage [90 and 180 days]

   Incidence of post-operative bile leakage (liver only)

6. Post-hepatectomy haemorrhage (PHH) [30 days]

   Incidence of post-operative bleeding (liver only)

7. Post-operative pancreatic juice leakage [90 and 180 days]

   Incidence of post-operative pancreatic juice leakage (pancreas only)

8. Post-pancreatectomy haemorrhage (PPH) [30 days]

   Incidence of post-operative bleeding (pancreas only)

9. (Serious) Adverse Device Effects [16 months]

   Incidence of (Serious) Adverse Device Effects

10. Incidence of transfusion [16 months]

    Incidence of transfusion

11. Length of hospital stay [30 days]

    Length of hospital stay

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Preoperative inclusion criteria:

Subjects will be eligible according the following criteria:

1. Subjects who are able to provide a written informed consent prior to participating in the clinical investigation.

2. Subjects who are ≥ 18 years old.

3. Subjects who are able to comply with the follow-up or other requirements.

4. Subjects who are planned for an elective hepatic resection or distal pancreatectomy.

During the surgery, the patients also need to comply with the intraoperative criteria.

Intraoperative inclusion criteria:

Subjects will be eligible according the following criteria:

1. Patch is applied manually (during open procedure, conversion procedure, or laparoscopic assisted procedure).

Exclusion Criteria:

Preoperative exclusion criteria

Subjects who meet any of the following criteria will be excluded from participation:

1. Female subjects who are pregnant and/or breastfeeding.

2. Subjects with a known allergy to any of the components of the Sealing Device (Polyurethane (SDPU), 8-ArmPEG40k-SC (SDA), Disodium Hydrogen Phosphate (Na2HPO4) (BS) and DC-Green #6 (SDD)).

3. Subject with bleeding disorders requiring anti-coagulation medication (except acetylsalicylic acid).

4. Subjects who receive double-coagulation.

5. Subjects who receive peritoneal dialysis.

6. Subjects who previously required liver transplantation.

7. Subjects with a presence of systemic infection.

8. Subject who previously participated in this study, or in any investigational drug- or device study within 30 days of screening.

9. Subjects undergoing a procedure requiring an anastomosis (e.g. Klatskin tumours or Whipple).

Intraoperative exclusion criteria:

Subjects who meet any of the following criteria will be excluded from participation:

1. Subjects with multivisceral resections, except resection of spleen.

2. Not able to apply the patch(es) according to the Instructions For Use.

3. Total surgery requiring > 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2).

Additional for liver group:

1. Subjects with a Grade 3 or 4 of bleeding after primary closure after liver transection (Lewis 2016).

2. Subjects with liver cirrhosis Grade C on the Child-Turcotte-Pugh score.

Additional for pancreas group:

1. Subjects with a margin of < 1 cm between the defect and the portal vein.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Universitats Klinikum Hamburg-Eppendorf	Hamburg		Germany
2	University Hospital Oldenburg	Oldenburg		Germany

Sponsors and Collaborators

• Polyganics BV
• Genae

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Polyganics BV
• ClinicalTrials.gov Identifier: NCT04024956
• Other Study ID Numbers: CIP-3
• First Posted: Jul 18, 2019
• Last Update Posted: Apr 26, 2022
• Last Verified: Apr 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by Polyganics BV: Hepatic resection; Distal pancreatectomy; Sealant

Study Results

No Results Posted as of Apr 26, 2022